GlaxoSmithKline’s head of vaccine R&D is jumping to a wellness company concentrating on the microbiome as reports of an exodus start to spread
Back in the fall of 2019, GlaxoSmithKline vaccine R&D chief Emmanuel Hanon had plenty of good things to say about a wellness company called Viome and CEO Naveen Jain. He was particularly interested in Viome’s technology for analyzing the gut microbiome and how that could intersect with new vaccine research.
Today, Hanon is jumping ship to join his collaborator as R&D chief as reports circulate of an exodus at GSK’s big vaccine group.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.